Credit Suisse Group AG Initiates Coverage on Ra Pharmaceuticals Inc (RARX)
Stock analysts at Credit Suisse Group AG began coverage on shares of Ra Pharmaceuticals Inc (NASDAQ:RARX) in a note issued to investors on Monday. The firm set an “outperform” rating and a $19.00 price target on the stock. Credit Suisse Group AG’s price objective would indicate a potential upside of 46.15% from the company’s current price.
A number of other research analysts also recently weighed in on RARX. SunTrust Banks Inc. started coverage on shares of Ra Pharmaceuticals in a research report on Monday. They set a “buy” rating and a $32.00 target price for the company. Jefferies Group started coverage on shares of Ra Pharmaceuticals in a report on Monday. They issued a “buy” rating for the company.
Ra Pharmaceuticals (NASDAQ:RARX) opened at 13.00 on Monday. The firm’s market capitalization is $7.20 million. Ra Pharmaceuticals has a one year low of $12.33 and a one year high of $14.86. The stock’s 50 day moving average is $13.17 and its 200 day moving average is $13.17.
In other Ra Pharmaceuticals news, major shareholder Harry R. Weller acquired 338,462 shares of the business’s stock in a transaction that occurred on Monday, October 31st. The stock was bought at an average cost of $13.00 per share, with a total value of $4,400,006.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Rajeev M. Shah acquired 161,538 shares of the business’s stock in a transaction that occurred on Monday, October 31st. The stock was acquired at an average cost of $13.00 per share, with a total value of $2,099,994.00. The disclosure for this purchase can be found here.
About Ra Pharmaceuticals
Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.
Receive News & Stock Ratings for Ra Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.